Prothena Public Limited's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Prothena Public Limited's ROA in the second quarter of 2026?
Prothena Corporation Public Limited Company recorded a cumulative net loss of $-44 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -13.27%.

However, within the Healthcare sector 321 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3818, from total ROA ranking in the first quarter of 2026 at 4719.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-22.35 %	-28.01 %	-39.2 %	-40.97 %	-38.35 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-44	-151	-244	-280	-303
Return On Assets (TTM)	-13.27 %	-42.79 %	-63.01 %	-63.74 %	-60.59 %
PRTA's Total Ranking	# 3818	# 4719	# 4153	# 4178	# 3603
Total Assets (TTM) in million	304	350	327	345	391
Seq. Total Assets Change	-13.2 %	7.07 %	-5.39 %	-11.69 %	-19.52 %
Seq. Net Income Change	-	-	-	-	-

PRTA's 5 Years Annual ROA >> Back to PRTA Management Effectiveness >> Compare PRTA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 115
Sector	# 322
Overall	# 3281

Return On Assets Statistics
High	Average	Low
15.59 %	-21.76 %	-62.53 %
(Sep 30 2021)		(Sep 30 2025)

Financial Statements
Prothena Public Limited's Assets	$ 304 million	PRTA's Balance sheet
Prothena Public Limited's Income	$ -19 million	Quarterly PRTA's Income Statement
PRTA's Income by Division		See PRTA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-39.2 %	-21.55 %	-8.75 %	25.8 %	89.57 %
Total Assets in million	327	537	685	751	597
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-244	-122	-147	-117	67
Annual Return On Assets	-74.69 %	-22.76 %	-21.46 %	-15.58 %	11.22 %

PRTA's 5 Years Annual ROA >> Back to PRTA Management Effectiveness >> Compare PRTA ROA to its Competitors

More Return On Assets Ratios
PRTA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PRTA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PRTA's Competitors
Subscribers only: Roa for Prothena Public Limited's Suppliers
Subscribers only: Return On Assets for PRTA's Customers

You may also want to know
PRTA's Roi	PRTA's Inventory Turnover Ratio	PRTA's Growth Rates	PRTA's Dividend Comparisons
	PRTA's Profitability Ratios	PRTA's Asset Turnover Ratio	PRTA's Dividend Growth
PRTA's Roe	PRTA's Valuation Ratios	PRTA's Financial Strength Ratios	PRTA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T21:44:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.